IntelliPharmaCeutics International Inc. (IPCI)’s Financial Results Comparing With Vericel Corporation (NASDAQ:VCEL)

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) and Vericel Corporation (NASDAQ:VCEL), both competing one another are Biotechnology companies. We will compare their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IntelliPharmaCeutics International Inc. 2.40M 1.45 12.47M -3.26 0.00
Vericel Corporation 82.87M 9.30 13.09M -0.35 0.00

Table 1 demonstrates IntelliPharmaCeutics International Inc. and Vericel Corporation’s gross revenue, earnings per share and valuation.

Profitability

Table 2 has IntelliPharmaCeutics International Inc. and Vericel Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IntelliPharmaCeutics International Inc. -519.58% 599.2% -198.9%
Vericel Corporation -15.80% -22.9% -14.8%

Risk and Volatility

A 1.74 beta means IntelliPharmaCeutics International Inc.’s volatility is 74.00% more than Standard & Poor’s 500’s volatility. Competitively, Vericel Corporation’s 257.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 3.57 beta.

Liquidity

The Current Ratio of IntelliPharmaCeutics International Inc. is 0.2 while its Quick Ratio stands at 0.2. The Current Ratio of rival Vericel Corporation is 8 and its Quick Ratio is has 7.7. Vericel Corporation is better equipped to clear short and long-term obligations than IntelliPharmaCeutics International Inc.

Analyst Recommendations

Ratings and Recommendations for IntelliPharmaCeutics International Inc. and Vericel Corporation can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
IntelliPharmaCeutics International Inc. 0 0 0 0.00
Vericel Corporation 0 0 1 3.00

Competitively Vericel Corporation has a consensus price target of $23, with potential upside of 29.36%.

Institutional & Insider Ownership

Roughly 0.5% of IntelliPharmaCeutics International Inc. shares are owned by institutional investors while 79.7% of Vericel Corporation are owned by institutional investors. Insiders owned roughly 56.5% of IntelliPharmaCeutics International Inc.’s shares. On the other hand, insiders owned about 0.5% of Vericel Corporation’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
IntelliPharmaCeutics International Inc. -27.3% -54.71% -92.9% -94.67% -97.11% -97%
Vericel Corporation -0.23% 2.63% 37.57% 29.45% 257.96% 221.83%

For the past year IntelliPharmaCeutics International Inc. had bearish trend while Vericel Corporation had bullish trend.

Summary

Vericel Corporation beats on 9 of the 11 factors IntelliPharmaCeutics International Inc.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. It also develops Rexista Oxycodone, an abuse and alcohol-deterrent controlled-release oral formulation for the relief of pain; Regabatin XR and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; and Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease. In addition, the company offers Glucophage XR, an oral antihyperglycemia drug to treat type 2 diabetes; Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; and Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder. Further, it provides Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Intellipharmaceutics International Inc. has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.